AbbVie Inc. (NYSE: ABBV) announced that China’s National Medical Products Administration (NMPA) has approved RINVOQ (upadacitinib extended‑release tablets, 15 mg and 30 mg, once daily) for the treatment of adults and adolescents aged 12 years and older with severe alopecia areata – the product’s ninth approved indication in China, arriving just three months after its approval in the European Union.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | New indication |
| Product | RINVOQ – upadacitinib extended‑release tablets, 15 mg and 30 mg, once daily |
| Indication | Severe alopecia areata in adults and adolescents ≥12 years |
| Indication Count | Ninth approved indication for RINVOQ in China |
| Global Timing | Follows EU approval by three months |
| Announcement Date | 15 Oct 2026 |
Drug Profile & Mechanism of Action
- Molecule: Upadacitinib – a selective and reversible JAK (Janus kinase) inhibitor, administered as a once‑daily oral extended‑release tablet.
- Mechanism in Alopecia Areata: By inhibiting JAK‑mediated signaling, upadacitinib modulates the immune pathways driving autoimmune attack on hair follicles, enabling hair regrowth in severe disease.
- Dosing: Both the 15 mg and 30 mg once‑daily doses are approved, offering physicians flexibility across disease severity and response.
- Age Coverage: Label extends to adolescents from age 12, addressing a population with severe disease and limited approved treatment options.
- Platform Breadth: The alopecia areata approval makes RINVOQ a nine‑indication franchise in China, spanning immunology and dermatology.
Clinical Evidence – Phase 3 UP‑AA Program
| Endpoint (Week 24) | Result – Upadacitinib 15 mg | Result – Upadacitinib 30 mg | Comparator |
|---|---|---|---|
| Primary Endpoint – SALT Score ≤20 | Met | Met | Placebo |
| ≥80% Scalp Hair Coverage | Significantly higher proportion vs. placebo | Significantly higher proportion vs. placebo | Placebo |
| Key Secondary – Complete Scalp Hair Regrowth (SALT = 0) | Met | Met | – |
| Safety (Period A) | Generally consistent with profile in approved indications | Generally consistent with profile in approved indications | – |
The approval is based on data from the Phase 3 UP‑AA clinical program, which enrolled 1,399 subjects aged 12 to 64 years with severe alopecia areata. In the studies, both the 15 mg and 30 mg dose groups met the primary endpoint of a SALT Score ≤20 at Week 24 – corresponding to ≤20% scalp hair loss – with a significantly higher proportion of patients achieving ≥80% scalp hair coverage compared with placebo. Both dose groups in the two studies also met key secondary endpoints, including complete scalp hair regrowth (SALT = 0) at Week 24. The safety profile of both doses in Period A was generally consistent with that observed in upadacitinib’s approved indications.
Market Impact & Outlook
- Global Regulatory Momentum: China’s clearance just three months after EU approval underscores the accelerating global expansion of upadacitinib into alopecia areata and AbbVie’s prioritization of China NMPA filings.
- Severe Alopecia Areata Opportunity: Severe alopecia areata – including totalis and universalis forms – carries profound psychosocial burden with historically poor response to conventional therapies; oral JAK inhibitors have reshaped the treatment landscape.
- Competitive Positioning: RINVOQ joins an emerging class of approved JAK inhibitors for alopecia areata in major markets, competing on efficacy depth (including complete regrowth), adolescent eligibility, and once‑daily oral convenience.
- Franchise Economics: A ninth Chinese indication strengthens RINVOQ’s position within AbbVie’s immunology franchise amid the ongoing transition from legacy biologics to next‑generation small molecules.
- Access & Launch: Pricing, launch timing, and reimbursement (NRDL) status in China were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory developments, commercial rollout, and market expectations for RINVOQ (upadacitinib) in alopecia areata. Actual results may differ due to risks including reimbursement outcomes, competitive dynamics, safety signals, and market adoption. This summary is for informational purposes only and does not constitute investment advice.-Fineline Info & Tech
